LAVA Therapeutics N.V.

1.90 USD
-0.18 (-8.65%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

LAVA Therapeutics N.V. stock is up 3.83% since 30 days ago. The next earnings date is Apr 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January.

About LAVA Therapeutics N.V.

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. LAVA-051 is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.